.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Johnson and Johnson
Fish and Richardson
Dow
Cerilliant
Mallinckrodt
Chinese Patent Office
Farmers Insurance
Novartis
McKesson

Generated: February 21, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR
GEODON

« Back to Dashboard

Clinical Trial Listing

Trial ID Title Status Sponsor Phase Summary
NCT00044655 Switching Medication to Treat SchizophreniaCompletedNational Institute of Mental Health (NIMH)Phase 4 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00044655 Switching Medication to Treat SchizophreniaCompletedIcahn School of Medicine at Mount SinaiPhase 4 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00141271 A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I DepressionCompletedPfizerPhase 3 This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med.
NCT00208208 Geodon (Ziprasidone) for Posttraumatic Stress DisorderCompletedPfizerPhase 4 Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiveness of Geodon in civilian men and women who suffer from severe PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8).
NCT00208208 Geodon (Ziprasidone) for Posttraumatic Stress DisorderCompletedCreighton UniversityPhase 4 Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiveness of Geodon in civilian men and women who suffer from severe PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8).
NCT00208559 Ziprasidone in Children With Autism: A Pilot StudyCompletedDrexel University College of MedicinePhase 2 The purpose of this study is to see if the drug, ziprasidone, is effective in treating problems in adolescent associated with autism.
NCT00215150 Geodon for the Treatment of Refractory Social Anxiety DisorderCompletedPfizerPhase 2 The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone
NCT00215150 Geodon for the Treatment of Refractory Social Anxiety DisorderCompletedDuke UniversityPhase 2 The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone
NCT00237666 Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major DepressionCompletedLiebowitz, Michael R., M.D.Phase 4 The purpose of this study is to evaluate the antidepressant effectiveness of Geodon for the treatment of patients diagnosed with Bipolar II disorder who are currently experiencing a major depressive episode.
NCT00237666 Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major DepressionCompletedPfizerPhase 4 The purpose of this study is to evaluate the antidepressant effectiveness of Geodon for the treatment of patients diagnosed with Bipolar II disorder who are currently experiencing a major depressive episode.
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Conditions

Condition Name

Condition Name for GEODON
Intervention Trials
Bipolar Disorder 15
Schizophrenia 13
Schizoaffective Disorder 6
Healthy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for GEODON
Intervention Trials
Disease 16
Bipolar Disorder 16
Schizophrenia 13
Depression 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trial Locations

Trials by Country

Trials by Country for GEODON
Location Trials
United States 148
India 14
Malaysia 5
Ukraine 4
Colombia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for GEODON
Location Trials
Massachusetts 11
New York 11
California 10
North Carolina 8
Ohio 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress

Clinical Trial Phase

Clinical Trial Phase for GEODON
Clinical Trial Phase Trials
Phase 4 15
Phase 3 6
Phase 2/Phase 3 2
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for GEODON
Clinical Trial Phase Trials
Completed 31
Terminated 5
Recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors

Sponsor Name

Sponsor Name for GEODON
Sponsor Trials
Pfizer 21
Massachusetts General Hospital 4
Duke University 4
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for GEODON
Sponsor Trials
Other 52
Industry 24
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Julphar
US Department of Justice
Fuji
Argus Health
QuintilesIMS
Accenture
Healthtrust
Chubb
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot